Circio Holding

Mindre end 1K følgere

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

15.4

2026

Årsrapport '25

8.5

2026

Generalforsamling '26

31.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse26.2.2026, 06.00

Circio presents groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye

Selskabsmeddelelse19.2.2026, 06.00

Circio invites to R&D and corporate update webcast on 26 February 2026

Selskabsmeddelelse17.2.2026, 09.33

Circio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse16.2.2026, 06.00

CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING

Selskabsmeddelelse14.2.2026, 08.57

Circio announces allocation of stock options to key employees

Selskabsmeddelelse12.2.2026, 22.12

CRNA: Financial calendar

Selskabsmeddelelse12.2.2026, 11.19

Circio Holding ASA: Registration of share capital increase following rights issue and private placement

Selskabsmeddelelse6.2.2026, 10.48

Circio Holding ASA completes directed issue of NOK 3.6 million

Selskabsmeddelelse30.1.2026, 18.44

Circio Holding ASA – Mandatory notification of trade by primary insiders and close associates related to the rights issue and private placement

Selskabsmeddelelse30.1.2026, 13.11

Circio Holding ASA – Final results of the oversubscribed rights issue

Selskabsmeddelelse29.1.2026, 20.43

Circio Holding ASA announces substantially oversubscribed preliminary result of the rights issue

Selskabsmeddelelse29.1.2026, 08.32

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Selskabsmeddelelse29.1.2026, 06.00

Circio Holding ASA – Subscription period for the rights issue expires today

Selskabsmeddelelse28.1.2026, 12.37

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Selskabsmeddelelse23.1.2026, 06.00

Circio Holding ASA – Last day of trading in subscription rights in the rights issue

Pressemeddelelse22.1.2026, 09.50

Analyst Group publishes initiation report on Circio

Selskabsmeddelelse21.1.2026, 14.12

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Selskabsmeddelelse16.1.2026, 13.06

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Selskabsmeddelelse15.1.2026, 14.12

Circio Holding ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates

Selskabsmeddelelse15.1.2026, 06.00

Circio Holding ASA – Commencement of the subscription period for the rights issue

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.